HA14-1 10mM * 1mL in DMSO 10mM * 1mL in DMSO | Purity Not Available
Adooq Bioscience
HA14-1 interacts with Bcl-2 and inhibits the antiapoptotic effect of Bcl-2.
More Information Supplier PageSearch Results
HA14-1 100mg 100mg | Purity Not Available
Adooq Bioscience
HA14-1 interacts with Bcl-2 and inhibits the antiapoptotic effect of Bcl-2.
More Information Supplier PageHA14-1 10mg 10mg | Purity Not Available
Adooq Bioscience
HA14-1 interacts with Bcl-2 and inhibits the antiapoptotic effect of Bcl-2.
More Information Supplier PageGDC-0349 50mg 50mg | Purity Not Available
Adooq Bioscience
GDC-0349 is under evaluating the Safety and Tolerability in Patients with locally advanced or metastatic solid tumors or non hodgkin’s lymphoma.
More Information Supplier PageGDC-0349 5mg 5mg | Purity Not Available
Adooq Bioscience
GDC-0349 is under evaluating the Safety and Tolerability in Patients with locally advanced or metastatic solid tumors or non hodgkin’s lymphoma.
More Information Supplier PageGDC-0349 25mg 25mg | Purity Not Available
Adooq Bioscience
GDC-0349 is under evaluating the Safety and Tolerability in Patients with locally advanced or metastatic solid tumors or non hodgkin’s lymphoma.
More Information Supplier PageIxabepilone 25mg 25mg | Purity Not Available
Adooq Bioscience
Ixabepilone 5mg 5mg | Purity Not Available
Adooq Bioscience
INK 128 5mg 5mg | Purity Not Available
Adooq Bioscience
INK 128 is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity.
More Information Supplier PageINK 128 25mg 25mg | Purity Not Available
Adooq Bioscience
INK 128 is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR complex 2 or TORC2) with potential antineoplastic activity.
More Information Supplier Page